NJ Bio Expands Translational Research Capabilities Through L2P Research Labs Asset Acquisition
Key Insights
NJ Bio (search) has completed the asset purchase and full integration of L2P Research Labs (search)' services to bridge the translational research gap in drug development.
The acquisition addresses the high attrition rate of biological molecules moving past phase 1 clinical trials by providing comprehensive preclinical and translational research services.
NJ Bio (search) can now offer enhanced oncology (search) research capabilities including syngeneic, PDX, orthotopic, and humanized mouse models under GLP-aligned practices.
NJ Bio (search), Inc., a premier contract research and clinical manufacturing service provider based in Princeton, New Jersey, has announced the asset purchase and full integration of L2P Research Labs (search)' ("Lab to Pharmacy") research services, significantly expanding its translational research capabilities to address critical gaps in drug development.
Addressing High Clinical Trial Attrition Rates
The acquisition directly tackles a major industry challenge: the high attrition rate of biological molecules moving past phase 1 clinical trials. According to NJ Bio (search), translational research represents the key solution to overcoming this development bottleneck. The company previously specialized in preclinical and early-phase clinical research and development, with primary focus areas including ADCs (search), bioconjugation, custom synthesis, oligonucleotides, and mRNAs (search), but lacked comprehensive translational research services for its clients.
With the L2P integration, NJ Bio (search) can now offer a comprehensive suite of preclinical and translational research services under one umbrella, enabling seamless program progression from proof-of-concept to clinic. This integrated approach supports smarter data-driven decision-making, accelerates development timelines, and improves clinical outcomes, providing clients with better chances of success for phase 1 and beyond programs.
Enhanced Oncology Research Capabilities
L2P Research Labs (search) was well-recognized for its integrated preclinical R&D support, particularly in oncology (search) research and services supporting IND applications. Following the asset purchase, L2P Research Labs has ceased independent operations, with its portfolio of preclinical and translational research services now offered exclusively under NJ Bio (search).
The acquisition significantly expands NJ Bio (search)'s preclinical oncology (search) and translational research capabilities. The company can now provide syngeneic, PDX (patient-derived xenograft), orthotopic, and humanized mouse models, along with ILD (interstitial lung disease (search)) models and advanced in vivo imaging services. All services are conducted under GLP-aligned practices, with NJ Bio actively pursuing AAALAC accreditation and OLAW assurance to further strengthen its compliance and quality standards.
Strategic Integration and Service Portfolio
The integration represents a strategic move to bridge the translational research gap that has historically separated discovery research from clinical development. By combining NJ Bio (search)'s existing expertise in bioconjugation, synthetic organic chemistry, protein-based biopharmaceuticals, and GMP manufacturing with L2P's translational research capabilities, the company now offers a more comprehensive solution for biotech and pharmaceutical clients.
NJ Bio (search) operates from multiple locations, including its Princeton, New Jersey headquarters and additional chemistry facilities in Bristol, Pennsylvania, and Mumbai, India. The expanded service portfolio positions the company to provide more integrated chemistry and biology services across the drug discovery and development continuum.